Bacopaside I

Bacopaside I at a Glance

Bacopaside I is a triterpenoid saponin of Bacopa monnieri — the Ayurvedic nootropic herb known as brahmi or water hyssop. Structurally it is a dammarane-type pseudojujubogenin glycoside carrying an unusual sulfonyl (sulfate) group on its sugar chain, which distinguishes it from its close relative bacopaside II; the two are among the principal saponins that accompany the standardised bacoside A marker complex ^{1Reference 1Chakravarty AK et al. · 2001Bacopaside I and II: two pseudojujubogenin glycosides from Bacopa monnieraView study →}.

Its research profile is a preclinical spread across several unrelated areas: neuroprotection after cerebral ischemia, memory improvement in an Alzheimer’s mouse model, antidepressant-like behaviour, and — through inhibition of the water channel aquaporin-1 — anticancer / anti-angiogenic and anti-arthritic effects ^{2,3,4,5,8,9Reference 2Liu X et al. · 2013Neuroprotective effects of bacopaside I in ischemic brain injuryView study →Reference 3Le XT et al. · 2015AnimalProtective effects of Bacopa monnieri on ischemia-induced cognitive deficits in mice: the possible contribution of bacopaside I and underlying mechanismView study →Reference 4Li Y et al. · 2016AnimalBacopaside I ameliorates cognitive impairment in APP/PS1 mice via immune-mediated clearance of β-amyloidView study →Reference 5Kamkaew N et al. · 2019AnimalVasodilatory effects and mechanisms of action of Bacopa monnieri active compounds on rat mesenteric arteriesView study →Reference 8Tomita Y et al. · 2021In vitroIn vitro synergistic inhibition of HT-29 proliferation and 2H-11 and HUVEC tubulogenesis by bacopaside I and II is associated with Ca²⁺ flux and loss of plasma membrane integrityView study →Reference 9Huang Y et al. · 2025Bacopaside I, acting as an aquaporin 1 inhibitor, ameliorates rheumatoid arthritis via suppressing aquaporin 1-mediated autophagyView study →}.

The honest headline sits up front: every finding below is from cell or animal work, and there are no human trials of isolated bacopaside I. All of Bacopa’s clinical cognitive evidence belongs to whole standardised extracts (CDRI 08, BacoMind), where bacopaside I is one contributor among many bacosides ^{10Reference 10Aguiar S · 2013ReviewNeuropharmacological review of the nootropic herb Bacopa monnieriView study →}.

Bacopaside I vs. Bacopaside II & the Bacoside A Complex

The single most useful thing to hold onto about this molecule is where it sits among the Bacopa saponins — the naming is a common source of confusion.

Both bacopaside I and bacopaside II are pseudojujubogenin glycosides first isolated together and structurally elucidated in 2001 ^{1Reference 1Chakravarty AK et al. · 2001Bacopaside I and II: two pseudojujubogenin glycosides from Bacopa monnieraView study →}. They differ in their 3-O sugar chain: bacopaside I carries a distinctive 6-O-sulphonyl (sulfate) group that bacopaside II lacks ^{1Reference 1Chakravarty AK et al. · 2001Bacopaside I and II: two pseudojujubogenin glycosides from Bacopa monnieraView study →}. That charged sulfate is a genuine structural fingerprint, not a footnote — it changes the molecule’s polarity and likely its membrane behaviour.

“Bacoside A” is not a single molecule but a standardising marker mixture (bacoside A3, bacopaside II, bacopasaponin C and the jujubogenin isomer of bacopasaponin C). Bacopaside I is a major Bacopa saponin that is routinely co-quantified alongside the bacoside A markers and is often reported together with them, but it is a defined individual compound in its own right, rather than a subcomponent of that HPLC sum. When a study says “bacopaside I,” it means this one sulfated saponin; when it says “bacoside A,” it means the whole marker complex ^{1,10Reference 1Chakravarty AK et al. · 2001Bacopaside I and II: two pseudojujubogenin glycosides from Bacopa monnieraView study →Reference 10Aguiar S · 2013ReviewNeuropharmacological review of the nootropic herb Bacopa monnieriView study →}.

What It's Used For

Bacopaside I has been tested as an isolate more often than most single Bacopa saponins, but always preclinically. The evidence clusters around the CNS (ischemia, memory, mood) and around a distinct aquaporin-1-blocking mechanism that drives its anticancer and anti-arthritic work.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. There are no human isolate data, so scores stay modest by design.

01Cerebral Ischemia / NeuroprotectionShaky42%Two rodent in-vivo models: ↓ infarct, ↑ ATP/antioxidants, PKC + PI3K/Akt ^{2,3Reference 2Liu X et al. · 2013Neuroprotective effects of bacopaside I in ischemic brain injuryView study →Reference 3Le XT et al. · 2015AnimalProtective effects of Bacopa monnieri on ischemia-induced cognitive deficits in mice: the possible contribution of bacopaside I and underlying mechanismView study →}

02Memory & CognitionShaky38%APP/PS1 Alzheimer’s mouse: ↑ spatial memory, ↓ fibrillar Aβ ^{3,4Reference 3Le XT et al. · 2015AnimalProtective effects of Bacopa monnieri on ischemia-induced cognitive deficits in mice: the possible contribution of bacopaside I and underlying mechanismView study →Reference 4Li Y et al. · 2016AnimalBacopaside I ameliorates cognitive impairment in APP/PS1 mice via immune-mediated clearance of β-amyloidView study →}

03Anticancer / Anti-AngiogenicShaky34%In-vitro synergy with bacopaside II; AQP1 block, Ca²⁺ flux ^{7,8Reference 7Palethorpe HM et al. · 2019Bacopasides I and II act in synergy to inhibit the growth, migration and invasion of breast cancer cell linesView study →Reference 8Tomita Y et al. · 2021In vitroIn vitro synergistic inhibition of HT-29 proliferation and 2H-11 and HUVEC tubulogenesis by bacopaside I and II is associated with Ca²⁺ flux and loss of plasma membrane integrityView study →}

04Antidepressant-LikeShaky28%One rodent study (forced-swim / tail-suspension) ^{6Reference 6Zhou Y et al. · 2007AnimalTriterpene saponins from Bacopa monnieri and their antidepressant effects in two mice modelsView study →}

05Vascular & Anti-InflammatoryShaky26%Ex-vivo vasorelaxation ^{5Reference 5Kamkaew N et al. · 2019AnimalVasodilatory effects and mechanisms of action of Bacopa monnieri active compounds on rat mesenteric arteriesView study →}; rat arthritis via AQP1 ^{9Reference 9Huang Y et al. · 2025Bacopaside I, acting as an aquaporin 1 inhibitor, ameliorates rheumatoid arthritis via suppressing aquaporin 1-mediated autophagyView study →}

Mechanisms

The unifying thread is aquaporin-1 inhibition — the same molecular action that reduces endothelial tubulogenesis and cancer-cell migration also underlies the anti-arthritic effect. The CNS neuroprotection runs on a separate axis (antioxidant + PI3K/Akt/PKC survival signalling).

Pharmacokinetics

No dedicated human or isolated-animal PK study of bacopaside I exists. As a large, sulfated triterpenoid saponin it carries the class liabilities — poor passive membrane permeability, susceptibility to gastric and gut-microbial hydrolysis, and expected low oral bioavailability — the same profile that limits Bacopa bacosides generally. The charged 6-O-sulphonyl group makes passive absorption even less likely than for neutral saponins. That said, rodent CNS efficacy at 10–50 mg/kg (oral and systemic) implies some brain exposure is achieved in animals; the quantitative bridge to human oral dosing is unmeasured. This is the central caveat for every in-vitro concentration cited above.

Clinical Trials

There are no human trials of isolated bacopaside I. All Bacopa monnieri clinical experience — the randomised cognitive and memory trials — uses whole standardised extracts (CDRI 08 / KeenMind, BacoMind) standardised to total bacosides, which cannot be attributed to this single saponin ^{10Reference 10Aguiar S · 2013ReviewNeuropharmacological review of the nootropic herb Bacopa monnieriView study →}.

Last checked: July 2026.

Isolate vs. Plant Studies

Bacopaside I is unusual among Bacopa saponins in that much of its evidence is genuinely on the isolated molecule — the ischemia, Alzheimer’s-model, antidepressant, anticancer and arthritis studies all dosed purified bacopaside I (or bacopaside I plus II) rather than whole extract ^{2,3,4,6,7,8,9Reference 2Liu X et al. · 2013Neuroprotective effects of bacopaside I in ischemic brain injuryView study →Reference 3Le XT et al. · 2015AnimalProtective effects of Bacopa monnieri on ischemia-induced cognitive deficits in mice: the possible contribution of bacopaside I and underlying mechanismView study →Reference 4Li Y et al. · 2016AnimalBacopaside I ameliorates cognitive impairment in APP/PS1 mice via immune-mediated clearance of β-amyloidView study →Reference 6Zhou Y et al. · 2007AnimalTriterpene saponins from Bacopa monnieri and their antidepressant effects in two mice modelsView study →Reference 7Palethorpe HM et al. · 2019Bacopasides I and II act in synergy to inhibit the growth, migration and invasion of breast cancer cell linesView study →Reference 8Tomita Y et al. · 2021In vitroIn vitro synergistic inhibition of HT-29 proliferation and 2H-11 and HUVEC tubulogenesis by bacopaside I and II is associated with Ca²⁺ flux and loss of plasma membrane integrityView study →Reference 9Huang Y et al. · 2025Bacopaside I, acting as an aquaporin 1 inhibitor, ameliorates rheumatoid arthritis via suppressing aquaporin 1-mediated autophagyView study →}. That is a real strength: it means the effects are attributable to this compound, not inferred from a mixture.

The transferability caveat runs the other way. Human Bacopa evidence is entirely whole-extract — the memory and cognitive RCTs use CDRI 08 or BacoMind standardised to total bacosides ^{10Reference 10Aguiar S · 2013ReviewNeuropharmacological review of the nootropic herb Bacopa monnieriView study →} — so the isolate’s animal results have never been confirmed in people, and the poor, unmeasured oral bioavailability of a sulfated saponin means whole-herb intake may never reach the concentrations that were active in vitro. The vasorelaxation work is a useful reminder that in the whole plant, co-occurring flavonoids (luteolin, apigenin) can out-perform the saponins ^{5Reference 5Kamkaew N et al. · 2019AnimalVasodilatory effects and mechanisms of action of Bacopa monnieri active compounds on rat mesenteric arteriesView study →}.

Prevalence in Nature

Bacopaside I is, for practical purposes, a Bacopa monnieri-specific metabolite: it is one of the principal triterpenoid saponins of brahmi (water hyssop), the small creeping wetland herb that is the near-sole documented source ^{1Reference 1Chakravarty AK et al. · 2001Bacopaside I and II: two pseudojujubogenin glycosides from Bacopa monnieraView study →}. It occurs together with bacopaside II, the bacoside A3 / bacopasaponin markers, and minor bacopasaponins, alongside the plant’s sterols (including beta-sitosterol) ^{1,10Reference 1Chakravarty AK et al. · 2001Bacopaside I and II: two pseudojujubogenin glycosides from Bacopa monnieraView study →Reference 10Aguiar S · 2013ReviewNeuropharmacological review of the nootropic herb Bacopa monnieriView study →}.

Quantified content is usually reported for the bacoside A marker complex (roughly 2–6% of the dry herb, varying severalfold with genotype, region and processing), rather than for bacopaside I in isolation; a clean, separately-measured bacopaside I percentage across sources is not well documented, which is why standardised commercial extracts are defined by total bacoside content, not by this individual saponin ^{10Reference 10Aguiar S · 2013ReviewNeuropharmacological review of the nootropic herb Bacopa monnieriView study →}.

Discovery & Synthesis

Bacopaside I was first isolated and named in 2001 by A.K. Chakravarty, T. Sarkar and colleagues at the Indian Institute of Chemical Biology (Calcutta), reported together with bacopaside II. Using 2D-NMR and other spectral analysis they elucidated its structure as 3-O-α-L-arabinofuranosyl-(1→2)-[6-O-sulphonyl-β-D-glucopyranosyl-(1→3)]-α-L-arabinopyranosyl pseudojujubogenin — the sulfated sugar chain being the feature that sets it apart from bacopaside II ^{1Reference 1Chakravarty AK et al. · 2001Bacopaside I and II: two pseudojujubogenin glycosides from Bacopa monnieraView study →}. The name follows the “bacopaside” series applied to the Bacopa pseudojujubogenin glycosides.

There is no reported total synthesis of bacopaside I; the dammarane triterpene aglycone and its sulfated trisaccharide make de-novo synthesis impractical, and all material used in research is isolated from the plant (or bought as a plant-derived reference standard). This is a compound obtained by extraction, not manufacture.

Patents: not yet researched.

Toxicity & Safety

Bacopaside I carries a low flag. The justification is straightforward: it is a constituent of Bacopa monnieri, a herb with a well-documented low-toxicity profile as a nootropic ^{10Reference 10Aguiar S · 2013ReviewNeuropharmacological review of the nootropic herb Bacopa monnieriView study →}, and there is no molecule-specific organ-toxicity finding for the isolate — no hepatotoxic, cardiotoxic or SERCA-type liability of the kind that pushes some sibling saponins higher. In the rodent neuroprotection, memory and arthritis studies, doses of 10–50 mg/kg were used without reported toxicity ^{2,4,9Reference 2Liu X et al. · 2013Neuroprotective effects of bacopaside I in ischemic brain injuryView study →Reference 4Li Y et al. · 2016AnimalBacopaside I ameliorates cognitive impairment in APP/PS1 mice via immune-mediated clearance of β-amyloidView study →Reference 9Huang Y et al. · 2025Bacopaside I, acting as an aquaporin 1 inhibitor, ameliorates rheumatoid arthritis via suppressing aquaporin 1-mediated autophagyView study →}. The one generic caveat is the saponin class property of haemolysis at high concentration, and the honest limitation that safety here is inferred from preclinical work — no human isolate safety data exist.

Safety at a Glance

✅ Low / no toxicity

• No molecule-specific organ toxicity documented. Preclinical doses (10–50 mg/kg) were used without reported adverse effects, in a low-toxicity parent herb.
• Preclinical evidence only. No human safety, pharmacokinetic or interaction data for the isolate — safety is inferred, not established.
• Generic saponin caution. Like other triterpenoid saponins, potentially haemolytic at high concentration in vitro.

Reproductive/developmental safety of isolated bacopaside I has not been studied; pregnancy and lactation decisions belong to the Bacopa herb or product page where intake is decided, not to this molecule page.

Dosage

There is no established or safe human dose for isolated bacopaside I — it has never been dosed as an isolate in people. The figures in the literature are preclinical: rodent neuroprotection and cognition studies used roughly 10–50 mg/kg (oral or systemic) ^{2,4Reference 2Liu X et al. · 2013Neuroprotective effects of bacopaside I in ischemic brain injuryView study →Reference 4Li Y et al. · 2016AnimalBacopaside I ameliorates cognitive impairment in APP/PS1 mice via immune-mediated clearance of β-amyloidView study →}, and in-vitro work used micromolar concentrations. Any real-world human exposure is only as a minor fraction of standardised whole-Bacopa extracts (CDRI 08, BacoMind), which are dosed and standardised by total bacoside content — commonly 300–450 mg extract/day in cognitive trials — not by bacopaside I ^{10Reference 10Aguiar S · 2013ReviewNeuropharmacological review of the nootropic herb Bacopa monnieriView study →}. These are research figures, not a personal recommendation.

References

1. Chakravarty AK, Sarkar T, Masuda K, Shiojima K, Nakane T, Kawahara N (2001). Bacopaside I and II: two pseudojujubogenin glycosides from Bacopa monniera. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/11576596/
2. Liu X, Yue R, Zhang J, Shan L, Wang R, Zhang W (2013). Neuroprotective effects of bacopaside I in ischemic brain injury. Restorative Neurology and Neuroscience. https://pubmed.ncbi.nlm.nih.gov/23160060/
3. Le XT, Pham HT, Van Nguyen T, Nguyen KM, Tanaka K, Fujiwara H, Matsumoto K (2015). Protective effects of Bacopa monnieri on ischemia-induced cognitive deficits in mice: the possible contribution of bacopaside I and underlying mechanism. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/25660331/
4. Li Y, Yuan X, Shen Y, Zhao J, Yue R, Liu F, et al. (2016). Bacopaside I ameliorates cognitive impairment in APP/PS1 mice via immune-mediated clearance of β-amyloid. Aging (Albany NY). https://pubmed.ncbi.nlm.nih.gov/26946062/
5. Kamkaew N, Paracha TU, Ingkaninan K, Waranuch N, Chootip K (2019). Vasodilatory effects and mechanisms of action of Bacopa monnieri active compounds on rat mesenteric arteries. Molecules. https://pubmed.ncbi.nlm.nih.gov/31208086/
6. Zhou Y, Shen YH, Zhang C, Su J, Liu RH, Zhang WD (2007). Triterpene saponins from Bacopa monnieri and their antidepressant effects in two mice models. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/17343408/
7. Palethorpe HM, Smith E, Tomita Y, Nakhjavani M, Yool AJ, Price TJ, et al. (2019). Bacopasides I and II act in synergy to inhibit the growth, migration and invasion of breast cancer cell lines. Molecules. https://pubmed.ncbi.nlm.nih.gov/31574930/
8. Tomita Y, Smith E, Palethorpe HM, Nakhjavani M, Yool AJ, Price TJ, et al. (2021). In vitro synergistic inhibition of HT-29 proliferation and 2H-11 and HUVEC tubulogenesis by bacopaside I and II is associated with Ca²⁺ flux and loss of plasma membrane integrity. Pharmaceuticals (Basel). https://pubmed.ncbi.nlm.nih.gov/34066415/
9. Huang Y, Zhou MY, Li LL, Lv M, Xu ZS, Wu XJ, et al. (2025). Bacopaside I, acting as an aquaporin 1 inhibitor, ameliorates rheumatoid arthritis via suppressing aquaporin 1-mediated autophagy. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/39892307/
10. Aguiar S, Borowski T (2013). Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Research. https://pubmed.ncbi.nlm.nih.gov/23772955/

View all 10 references▾